Enzo Biochem Inc Asset Resilience Ratio
Enzo Biochem Inc asset resilience ratio. Enzo Biochem Inc (ENZ) has an Asset Resilience Ratio of 5.83% as of July 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ENZ days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Enzo Biochem Inc (2003–2024)
Asset resilience ratio of Enzo Biochem Inc from 2003 to 2024. This chart shows how Enzo Biochem Inc's Asset Resilience Ratio has changed over time. Read ENZ current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Enzo Biochem Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ENZ total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $5.00 Million | 5.83% |
| Total Liquid Assets | $5.00 Million | 5.83% |
Asset Resilience Insights
- Limited Liquidity: Enzo Biochem Inc maintains only 5.83% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Enzo Biochem Inc Industry Peers by Asset Resilience Ratio
Compare Enzo Biochem Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Voxel S.A.
WAR:VOX |
Diagnostics & Research | 0.32% |
|
Leveljump Healthcare Corp
V:JUMP |
Diagnostics & Research | 32.45% |
|
Prodia Widyahusada Tbk PT
JK:PRDA |
Diagnostics & Research | 7.82% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Enzo Biochem Inc Asset Resilience Ratio by Year (2003–2024)
Enzo Biochem Inc asset resilience ratio by year from 2003 to 2024. The table below shows the annual Asset Resilience Ratio data for Enzo Biochem Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-07-31 | 5.83% | $5.00 Million | $85.76 Million | -61.76pp |
| 2023-07-31 | 67.59% | $82.37 Million | $121.88 Million | +45.05pp |
| 2022-07-31 | 22.54% | $21.60 Million | $95.86 Million | -15.73pp |
| 2021-07-31 | 38.26% | $43.50 Million | $113.69 Million | -4.27pp |
| 2020-07-31 | 42.53% | $47.87 Million | $112.54 Million | -13.87pp |
| 2019-07-31 | 56.40% | $60.15 Million | $106.64 Million | -2.66pp |
| 2018-07-31 | 59.06% | $60.04 Million | $101.66 Million | -0.54pp |
| 2017-07-31 | 59.60% | $64.17 Million | $107.67 Million | -1.01pp |
| 2016-07-31 | 60.61% | $67.78 Million | $111.82 Million | -- |
| 2015-07-31 | 0.00% | $0.00 | $68.39 Million | -- |
| 2014-07-31 | 0.00% | $0.00 | $64.41 Million | -- |
| 2013-07-31 | 0.00% | $0.00 | $58.96 Million | -- |
| 2012-07-31 | 0.00% | $0.00 | $69.12 Million | -- |
| 2011-07-31 | 9.13% | $10.00 Million | $109.47 Million | -12.39pp |
| 2010-07-31 | 21.53% | $24.81 Million | $115.25 Million | -11.00pp |
| 2009-07-31 | 32.53% | $43.31 Million | $133.13 Million | +26.77pp |
| 2005-07-31 | 5.76% | $6.71 Million | $116.47 Million | -9.86pp |
| 2004-07-31 | 15.63% | $17.24 Million | $110.33 Million | +2.55pp |
| 2003-07-31 | 13.08% | $15.15 Million | $115.88 Million | -- |
About Enzo Biochem Inc
Enzo Biochem, Inc., a life sciences company, engages in the labeling and detection technologies from DNA to whole cell analysis in the United States and internationally. The company offers labels, dyes, antibodies, genomic probes, immunoassays, biochemicals, and proteins are used to label, detect, and visualize a biological target of interest in drug discovery exploration and drug development pro… Read more